The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms

Annals of Hematology

Volumn 89, Issue 10, 2010, Pages 979-983

  Trifa, Adrian P ^a   Cucuianu, Andrei ^b   Petrov, Ljubomir ^b   Urian, Laura ^b   Militaru, Mariela S ^a   Dima, Delia ^b   Pop, Ioan V ^a   Popp, Radu A ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

Author keywords

JAK2 46 1 haplotype; JAK2 rs10974944 SNP; JAK2 V617F; Myeloproliferative neoplasms

Indexed keywords

JANUS KINASE 2;

ALLELE; ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MUTANT; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTHEMIA; BLOOD DISEASE; ENZYMOLOGY; GENETICS; MIDDLE AGED; MUTATION;

ALLELES; GENOTYPE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77956681963     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0960-y     Document Type: Article

References (20)

1. AV Jones S Kreil K Zoi K Waghorn C Curtis L Zhang, et al. 2005 Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders Blood 106 2162 2168 10.1182/blood-2005-03-1320 1:CAS:528:DC%2BD2MXhtVWksLvF 15920007 (Pubitemid 41291734)
2. W Dameshek 1951 Some speculations on the myeloproliferative syndromes Blood 6 372 375 1:STN:280:DyaG3M%2FltVGnsw%3D%3D 14820991
3. R Kralovics F Passamonti AS Buser SS Teo R Tiedt JR Passweg, et al. 2005 A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 1779 1790 10.1056/NEJMoa051113 1:CAS:528:DC%2BD2MXjsFyhsLw%3D 15858187 (Pubitemid 40570926)
4. C James V Ugo JP Le Couedic J Staerk F Delhommeau C Lacout, et al. 2005 A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera Nature 434 1144 1148 10.1038/nature03546 1:CAS:528: DC%2BD2MXjsF2ltbk%3D 15793561 (Pubitemid 40663494)
5. EJ Baxter LM Scott PJ Campbell C East N Fourouclas S Swanton, et al. 2005 Acquired mutations of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 1054 1061 1:CAS:528:DC%2BD2MXisFGrs7g%3D 15781101
6. RL Levine M Wadleigh J Cools BL Ebert G Wernig BJ Huntly, et al. 2005 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 387 397 10.1016/j.ccr.2005.03.023 1:CAS:528:DC%2BD2MXjvFSku7o%3D 15837627 (Pubitemid 40544655)
7. A Tefferi JW Vardiman 2008 Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms Leukemia 22 14 22 10.1038/sj.leu.2404955 1:CAS:528:DC%2BD1cXmsV2jtA%3D%3D 17882280
8. R Kralovics SS Teo S Li A Theocharides AS Buser A Tichelli, et al. 2006 Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders Blood 108 1377 1380 10.1182/blood-2005-11-009605 1:CAS:528:DC%2BD28Xot1ymu70%3D 16675710 (Pubitemid 44232040)
9. A Pardanani BL Fridley TL Lasho DG Gilliland A Tefferi 2008 Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders Blood 111 2785 2789 10.1182/blood-2007-06-095703 1:CAS:528:DC%2BD1cXivFaktbc%3D 18006699
10. F Delhommeau S Dupont V Della Valle C James S Trannoy A Masse, et al. 2009 Mutation in TET2 in myeloid cancers N Engl J Med 360 2289 2301 10.1056/NEJMoa0810069 19474426
11. A Tefferi A Pardanani KH Lim O Abdel-Wahab TL Lasho J Patel, et al. 2009 TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis Leukemia 23 905 911 10.1038/leu.2009.47 1:CAS:528:DC%2BD1MXlslCrurY%3D 19262601
12. N Carbuccia A Murati V Trouplin M Brecqueville J Adelaide J Rey, et al. 2009 Mutations of ASXL1 gene in myeloproliferative neoplasms Leukemia 23 2183 2186 10.1038/leu.2009.141 1:CAS:528:DC%2BD1MXhtl2hsrjJ 19609284
13. TL Lasho A Pardanani RF McClure RA Mesa RL Levine DG Gilliland, et al. 2006 Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time Br J Haematol 135 683 687 10.1111/j.1365-2141.2006.06348.x 1:CAS:528:DC%2BD2sXitl2mtQ%3D%3D 17107350 (Pubitemid 44674079)
14. AV Jones A Chase RT Silver D Oscier K Zoi YL Wang, et al. 2009 JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms Nat Genet 41 4 446 449 10.1038/ng.334 1:CAS:528:DC%2BD1MXjtFCis7c%3D 19287382
15. D Olcaydu A Harutyunyan R Jäger T Berg B Gisslinger I Pabinger, et al. 2009 A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms Nat Genet 41 4 450 454 10.1038/ng.341 1:CAS:528:DC%2BD1MXjtFCisb4%3D 19287385
16. O Kilpivaara S Mukherjee AM Schram M Wadleigh A Mullally BL Ebert, et al. 2009 A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms Nat Genet 41 4 455 459 10.1038/ng.342 1:CAS:528:DC%2BD1MXjtFCisLw%3D 19287384
17. A Pardanani TL Lasho CM Finke N Gangat AP Wolanskyj CA Hanson, et al. 2010 The JAK2 46/1 confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical corelates in a study of 226 consecutive patients Leukemia 24 1 110 114 10.1038/leu.2009.226 1:STN:280:DC%2BC3c%2FhvF2ntg%3D%3D 19847198
18. A Tefferi TL Lasho MM Patnaik CM Finke K Hussein WJ Hogan, et al. 2010 JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival Leukemia 24 1 105 119 10.1038/leu.2009.225 1:STN:280:DC%2BC3c%2FhvF2ntw%3D%3D 19847199
19. V617F Acta Haematol 123 2 84 87 10.1159/000264954 20016140
20. D Olcaydu RC Skoda R Looser S Li M Cazzola D Pietra, et al. 2009 The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera Leukemia 23 1924 1926 10.1038/leu.2009.110 1:STN:280:DC%2BD1Mnos1ymsg%3D%3D 19440215